After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart ...

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

Novo Nordisk Foundation, ultimate parent of weight loss drugs Ozempic and Wegovy, awards a grant to University of Copenhagen ...

Find insight on Novo Nordisk, WELL Health Technologies and more in the latest Market Talks covering Health Care.

US President Donald Trump is set to unveil reciprocal tariffs on Wednesday, with ongoing uncertainties surrounding his policies weighing on market sentiment. European stock markets posted their first ...

The attorneys general sent a letter saying the FDA needs to take action because high demand for the weight loss drugs paired with shortages has created a market for counterfeits.